Omeros Co. (NASDAQ:OMER) Given Consensus Recommendation of "Moderate Buy" by Analysts

Omeros Co. (NASDAQ:OMER - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five research firms that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $22.50.

Several brokerages recently issued reports on OMER. Needham & Company LLC reissued a "hold" rating on shares of Omeros in a research note on Friday, January 17th. Rodman & Renshaw started coverage on shares of Omeros in a research report on Thursday, November 14th. They issued a "buy" rating and a $9.00 price target for the company. RODMAN&RENSHAW raised shares of Omeros to a "strong-buy" rating in a research report on Thursday, November 14th. StockNews.com downgraded shares of Omeros from a "hold" rating to a "sell" rating in a research report on Wednesday, March 5th. Finally, Cantor Fitzgerald reissued a "neutral" rating on shares of Omeros in a research note on Thursday, November 14th.

Omeros Stock Up 5.0 %

Shares of OMER traded up $0.35 during mid-day trading on Friday, reaching $7.39. The company's stock had a trading volume of 472,607 shares, compared to its average volume of 529,585. The company has a market cap of $428.25 million, a price-to-earnings ratio of -3.20 and a beta of 2.03. The business has a fifty day moving average of $8.98 and a 200 day moving average of $7.09. Omeros has a 1 year low of $2.61 and a 1 year high of $13.60.

Remove Ads

Hedge Funds Weigh In On Omeros

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. increased its stake in shares of Omeros by 4.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company's stock worth $1,926,000 after purchasing an additional 18,454 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company's stock valued at $49,000 after buying an additional 7,016 shares in the last quarter. HighTower Advisors LLC raised its holdings in Omeros by 7.2% during the third quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company's stock valued at $235,000 after buying an additional 4,000 shares in the last quarter. State Street Corp boosted its stake in shares of Omeros by 0.3% during the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company's stock worth $4,867,000 after acquiring an additional 3,839 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new position in shares of Omeros during the 3rd quarter valued at about $305,000. Institutional investors own 48.79% of the company's stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.